
## **CENTER FOR DRUG EVALUATION AND** RESEARCH

**APPLICATION NUMBER: 21-165/s001** 

## **APPROVAL LETTER**



Food and Drug Administration Rockville, MD 20857

NDA 21-165/S-001

Schering Corporation 2000 Galloping Hill Road Kenilworth, NJ 07033

Attention: Joseph Lamendola, Ph.D.

Vice President, Regulatory Affairs

Dear Dr. Lamendola:

Please refer to your supplemental new drug application dated February 6, 2002, received February 7, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Clarinex (desloratedine) Tablets.

This supplemental new drug application provides for revisions to the package insert to incorporate chronic idiopathic urticaria and perennial allergic rhinitis that were approved under NDAs 21-297 and 21-363 respectively.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text, which includes minor revisions as discussed and agreed upon in a telephone conversations between Daniel McHugh of Schering Corporation and Anthony Zeccola of this division. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed draft labeling including the minor revision.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 21-165. — Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42 Food and Drug Administration 5600 Fishers Lane Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2 FDA 5600 Fishers Lane Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Anthony M. Zeccola, Regulatory Management Officer, at 301-827-1058.

Sincerely,

{See appended electronic signature page}

Robert J. Meyer, M.D.

Director

Division of Pulmonary and Allergy Drug Products

Office of Drug Evaluation II

Center for Drug Evaluation and Research

APPEARS THIS WAY
ON ORIGINAL

